Better-than-Expected Label for BMS' Ipilimumab in Melanoma
Bristol-Myers Squibb Co. is planning a quick rollout of ipilimumab following its Friday approval as the first drug to demonstrate improvement in overall survival in metastatic melanoma.
The New York-based pharma firm will get the drug, branded Yervoy, to patients "in a matter of weeks," said BMS spokeswoman Jennifer Fron Mauer. "We are all ready to go."
Market Data 
Markets 
AI
